IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023

~ INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving healthy tissue. ~ Data supports the potential for this next-generation CAR-T technology in previously “undruggable” solid- and liquid-tumor targets.

Daniel Carlson

March 16, 2023

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.